← Eichor
Study identifier: NCT06751030 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Community, Home-based Education, Screening Services Strategy to Increase Cervical Cancer Control Access for HIV-Positive Women in Nigeria

Condition: HIV · Cervical Cancer  ·  Sponsor: Emory University

PhaseN/A
Planned participants1500
Who can joinFemale, 25 Years to 50 Years
Healthy volunteersNo

About this study

The goal of this observational study is to focus on adapting and implementing a program to promote HPV and cervical cancer (CC) screening and follow-up treatment for HIV-positive women, with three specific aims: * Adaptation: Use stakeholder deliberation to tailor the successful MoMent program for this population. * Implementation and Assessment: Deploy the adapted MoMent program and evaluate its reach, effectiveness, adoption, and fidelity. * Evaluation: Conduct a post-implementation process evaluation to identify barriers and facilitators to the program's maintenance and sustainability.

This description comes directly from the study's public registry record.

Talk to the study team

Lisa Flowers, MD, MPH  ·  404-712-3522  ·  Lflowe2@emory.edu

Always discuss trial participation with your own doctor first.

Locations (3)

APIN Health InitiativesAbuja, NigeriaRecruiting
University of IbadanIbadan, NigeriaRecruiting
Nigeria Institute of Medical Research (NIMRLagos, NigeriaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06751030